Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify

Medicare’s new GLP-1 Bridge demonstration is lowering the monthly price of certain weight-management medicines to $50 for qualifying beneficiaries, opening a possible route to treatment that has been beyond reach for many older adults. Yet the program’s rules create a striking divide: some people with serious related illnesses are directed away from the discount and back to their usual drug plans, where the amount they must pay can be far higher.

The 18-month experiment began in July and covers three medicines: Wegovy, the KwikPen version of Zepbound, and the oral drug Foundayo. Medicare is testing whether helping eligible people obtain these drugs for weight loss and long-term weight management could reduce costs later. Applicants must have Medicare Part D, the prescription-drug benefit, but their request is handled through a separate system operated for the Centers for Medicare & Medicaid Services rather than by their Part D insurer.

Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify

For many applicants, eligibility rests on body-mass index and medical history. People with a BMI of at least 35 may qualify when a medication is prescribed. Those with a BMI from 27 through 34 may also be eligible if they have specified conditions, including prediabetes or cardiovascular disease. The structure reflects a narrow policy goal: make a lower-cost option available to people seeking these medicines for weight management who do not otherwise receive Part D coverage for that purpose.

That boundary is also the program’s central limitation. Federal law has traditionally prevented Medicare from paying for drugs when they are prescribed only for weight loss. But a person who has an FDA-approved condition for treatment with a GLP-1, including Type 2 diabetes or moderate-to-severe obstructive sleep apnea, is not eligible for the Bridge price on that basis. Instead, the person is referred to Part D coverage, which may leave sizeable copayments in place.

Jeff La Marca, a 68-year-old from Basking Ridge, New Jersey, encountered that problem after receiving a Zepbound prescription in January. He said the medicine’s roughly $750 monthly price put it out of reach. The new pilot appeared to offer an affordable alternative, but his request was rejected. La Marca has severe obstructive sleep apnea, a diagnosis that places him outside the $50 Bridge benefit even though he believes his weight and other health risks would otherwise support eligibility.

His experience illustrates the difference between having drug coverage and being able to use it. Patients sent to Part D can face several layers of access requirements, including prior authorization and step therapy, in which other, often less expensive treatments must be tried first. A primary-care doctor interviewed about the program said beneficiaries can spend months clearing those hurdles and still learn at the pharmacy that a GLP-1 copay runs from $200 to $600 a month or more.

The access questions come as GLP-1 medicines have become widely used but remain financially difficult for many patients. About one in five U.S. adults has taken one of the drugs, and affordability is a concern even among people with insurance. Research on Medicare plan coverage has found rising out-of-pocket expenses for recipients and near-universal use of prior authorization, adding administrative friction to the cost barrier.

The fiscal scale of the pilot will depend on enrollment, and the federal government has not published its own cost projection. Juliette Cubanski of KFF estimated that 3.8 million people could qualify. If one-quarter participate and stay on the drugs for all 18 months, her estimate puts Medicare’s cost near $3.3 billion; participation by three-quarters could take it to $10 billion. Extending the discount to an additional 5.9 million people already eligible through Part D would add billions more.

CMS says the early rollout has moved quickly, with most authorization decisions completed in less than 12 hours and thousands of eligible beneficiaries obtaining medicines at pharmacies nationwide. The next test will be whether that speed and lower price translate into durable access without widening the gap for patients whose diagnoses make treatment medically relevant but remove them from the pilot’s subsidized pathway. For now, people such as La Marca remain caught between a recognized need for care and coverage that may still be unaffordable.